Aclaris Therapeutics Inc., of Malvern, Pa., added Andrew Schiff to its board.

Alkahest Inc., of San Carlos, Calif., appointed Helen Jenkins chief operating officer.

Amag Pharmaceuticals Inc., of Waltham, Mass., appointed Oscar Sanchez vice president of quality.

Aridis Pharmaceuticals Inc., of San Jose, Calif., named Alan H. Cohen senior vice president of clinical and medical affairs.

Clearside Biomedical Inc., of Alpharetta, Ga., added George Lasezkay to its board.

Medigene AG, of Martinsried, Germany, appointed Micha Drukker, Irmela Jeremias, Peter H. Krammer, Manfred Rüdiger, Lawrence E. Samelson, Freda Stevenson, and Jolanda de Vries to its scientific advisory board, and named Ernst-Ludwig Winnacker chairman.

Orchard Therapeutics Ltd., of London, appointed Mark Rothera president and CEO.

Rubius Therapeutics Inc., of Cambridge, Mass., named David Epstein executive chairman.

Stealth Biotherapeutics Inc., of Boston, added Francis W. Chen, Kevin McLaughlin and Edward Owens to tis board.

Tyme Technologies Inc., of New York, named Jonathan Eckard chief scientific affairs officer.